Drugs / Clemastine
Clemastine
also known as
Clemastin · Clemastine Fumarate · Clemastina · Clemastine fumarate component of tavist-d · Clemastine hydrogen fumarate · HS-592 · NSC-756685 · Tavegil · +2 more
Small molecule targets HRH1 via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (3) | US (FDA) | TAVIST-1 | — | 1979-03-16 – 1996-10-31 | fda.gov ↗ |
| Approved | US (FDA) | TAVIST-1 | — | 1977-02-25 | fda.gov ↗ |
Trials 15
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07688746 | Jul 2026 → Mar 2028 expected | brain injury, periventricular leukomalacia | Bridget LaMonica Ostrem, M.D., Ph.D. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT02613091 | Apr → Sep 2016 | — | University of California, San Francisco | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06065670 | Sep 2026 → Oct 2028 expected | multiple sclerosis | University of California, San Francisco | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT05359653 | Aug 2023 → Jun 2027 expected | primary progressive multiple sclerosis, relapsing-remitting multiple sclerosis | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT06591091 | Dec 2025 → Dec 2026 expected | depressive disorder | University of Illinois at Chicago | Recruiting | No outcome recorded |
| Phase 2 | NCT06087757 | Apr 2024 → May 2026 overdue | Williams syndrome | Sheba Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06315972 | Apr 2024 → Nov 2026 expected | schizophrenia | LMU Klinikum | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06315699 | Mar 2024 → Mar 2025 | Williams syndrome, developmental delay with or without intellectual impairment or behavioral abnormalities | Qilu Hospital of Shandong University | Completed | No outcome recorded |
| Phase 2 | NCT05131828 | Mar 2022 → Mar 2025 | multiple sclerosis | Cambridge University Hospitals NHS Foundation Trust | Completed | No outcome recorded |
| Phase 2 | NCT02521311 | Feb 2017 → Aug 2028 expected | optic neuritis | University of California, San Francisco | Recruiting | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT05338450 | Aug 2022 → Aug 2025 | internuclear ophthalmoplegia, multiple sclerosis | Amsterdam UMC, location VUmc | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT01257061 | Sep 2012 → Apr 2013 | atopic eczema | EMS | Completed | No outcome recorded |
| Phase 3 | NCT01239719 | Mar → Jul 2011 | allergic disease, dermatitis | Azidus Brasil | Unknown | No outcome recorded |
| Phase 3 | NCT01125761 | Nov 2010 | dermatitis | Azidus Brasil | Withdrawn | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT03826004 | Feb → Jul 2019 | — | Chinese Academy of Medical Sciences, Fuwai Hospital | Completed | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1/2 | NCT07304024 Comparator | Mar 2025 → Jul 2028 expected | auditory perceptual disorders, demyelinating disease, noise induced hearing loss, sensorineural hearing loss disorder | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 2 | NCT02040298 Comparator | Jan 2014 → Sep 2015 | relapsing-remitting multiple sclerosis | University of California, San Francisco | Completed | No outcome recorded |
| Phase 2 | NCT00481676 Comparator | May 2007 → Apr 2009 | chronic urticaria | Novartis | Completed | No outcome recorded |
| Phase 2 | NCT01154361 Comparator | — | angioedema | Technical University of Munich | Completed | Met primary |
| Phase 3 | NCT01843530 Background | Nov 2013 → Oct 2018 | renin-angiotensin-aldosterone system-blocker-induced angioedema | Technical University of Munich | Completed | No outcome recorded |
| Phase 4 | NCT06118710 Background | Jun 2024 → Jun 2027 expected | cancer | Erasmus Medical Center | Recruiting | No outcome recorded |
Evidence & citations 15 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Clemastine | “Clemastine or Cetirizine prior to paclitaxel infusion according to local care standards” NCT06118710 ↗17“Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g applied 2 times / day at lesion” NCT01257061 ↗ “Clemastine” NCT06591091 ↗ |
| Known as | Clemastin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01843530 ↗ |
| Known as | Clemastina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1626 ↗ |
| Known as | Clemastine Fumarate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05359653 ↗ |
| Known as | Clemastine fumarate component of tavist-d | ChEMBL registry synonym — accepted as the source's own label CHEMBL1626 ↗ |
| Known as | Clemastine hydrogen fumarate | “Clemastine hydrogen fumarate 1.34 mg tablet for oral administration.” NCT05131828 ↗ |
| Known as | HS-592 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1626 ↗ |
| Known as | NSC-756685 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1626 ↗ |
| Known as | Tavegil | ChEMBL registry synonym — accepted as the source's own label CHEMBL1626 ↗ |
| Known as | Tavist | ChEMBL registry synonym — accepted as the source's own label CHEMBL1626 ↗ |
| Known as | Tavist-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1626 ↗ |
| Action | Inhibit | “histamine H1 receptor antagonist clemastine” NCT03826004 ↗1“Histamine H1 receptor antagonist” CHEMBL1626 ↗ |
| Modality | Small molecule | — CHEMBL1626 ↗ |
| Route | Topical | “a thin layer is applied on the lesions” NCT01125761 ↗ |
| Target | HRH1 | “Histamine H1 receptor antagonist” CHEMBL1626 ↗ |